QQQ   418.07 (-1.26%)
AAPL   165.13 (-1.14%)
MSFT   401.05 (-0.80%)
META   485.91 (-3.17%)
GOOGL   154.54 (-0.94%)
AMZN   175.54 (-2.05%)
TSLA   148.64 (-0.86%)
NVDA   796.73 (-5.90%)
AMD   149.37 (-3.68%)
NIO   3.83 (-4.25%)
BABA   68.96 (+0.12%)
T   16.41 (+0.49%)
F   12.13 (+0.58%)
MU   107.36 (-4.08%)
GE   149.59 (-2.19%)
CGC   8.12 (+3.70%)
DIS   112.30 (-0.12%)
AMC   3.23 (+10.62%)
PFE   25.83 (+1.73%)
PYPL   62.18 (+0.13%)
XOM   119.99 (+1.24%)
QQQ   418.07 (-1.26%)
AAPL   165.13 (-1.14%)
MSFT   401.05 (-0.80%)
META   485.91 (-3.17%)
GOOGL   154.54 (-0.94%)
AMZN   175.54 (-2.05%)
TSLA   148.64 (-0.86%)
NVDA   796.73 (-5.90%)
AMD   149.37 (-3.68%)
NIO   3.83 (-4.25%)
BABA   68.96 (+0.12%)
T   16.41 (+0.49%)
F   12.13 (+0.58%)
MU   107.36 (-4.08%)
GE   149.59 (-2.19%)
CGC   8.12 (+3.70%)
DIS   112.30 (-0.12%)
AMC   3.23 (+10.62%)
PFE   25.83 (+1.73%)
PYPL   62.18 (+0.13%)
XOM   119.99 (+1.24%)
QQQ   418.07 (-1.26%)
AAPL   165.13 (-1.14%)
MSFT   401.05 (-0.80%)
META   485.91 (-3.17%)
GOOGL   154.54 (-0.94%)
AMZN   175.54 (-2.05%)
TSLA   148.64 (-0.86%)
NVDA   796.73 (-5.90%)
AMD   149.37 (-3.68%)
NIO   3.83 (-4.25%)
BABA   68.96 (+0.12%)
T   16.41 (+0.49%)
F   12.13 (+0.58%)
MU   107.36 (-4.08%)
GE   149.59 (-2.19%)
CGC   8.12 (+3.70%)
DIS   112.30 (-0.12%)
AMC   3.23 (+10.62%)
PFE   25.83 (+1.73%)
PYPL   62.18 (+0.13%)
XOM   119.99 (+1.24%)
QQQ   418.07 (-1.26%)
AAPL   165.13 (-1.14%)
MSFT   401.05 (-0.80%)
META   485.91 (-3.17%)
GOOGL   154.54 (-0.94%)
AMZN   175.54 (-2.05%)
TSLA   148.64 (-0.86%)
NVDA   796.73 (-5.90%)
AMD   149.37 (-3.68%)
NIO   3.83 (-4.25%)
BABA   68.96 (+0.12%)
T   16.41 (+0.49%)
F   12.13 (+0.58%)
MU   107.36 (-4.08%)
GE   149.59 (-2.19%)
CGC   8.12 (+3.70%)
DIS   112.30 (-0.12%)
AMC   3.23 (+10.62%)
PFE   25.83 (+1.73%)
PYPL   62.18 (+0.13%)
XOM   119.99 (+1.24%)

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Altimmune, Inc. stock logo
ALT
Altimmune
$6.83
-0.9%
$9.54
$2.09
$14.84
$484.18M0.055.48 million shs1.87 million shs
Penumbra, Inc. stock logo
PEN
Penumbra
$201.91
+0.0%
$235.92
$180.93
$348.67
$7.81B0.51340,680 shs143,276 shs
PTRO
Petrominerals
$0.00
$0.01
$0.08
$53K2.5115,344 shsN/A
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Altimmune, Inc. stock logo
ALT
Altimmune
-2.13%-17.98%-21.17%-25.51%+15.41%
Penumbra, Inc. stock logo
PEN
Penumbra
-3.23%-9.21%-15.48%-19.31%-26.35%
PTRO
Petrominerals
0.00%0.00%0.00%0.00%0.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Altimmune, Inc. stock logo
ALT
Altimmune
1.1183 of 5 stars
3.32.00.00.01.71.70.0
Penumbra, Inc. stock logo
PEN
Penumbra
4.9342 of 5 stars
4.43.00.03.82.42.53.1
PTRO
Petrominerals
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Altimmune, Inc. stock logo
ALT
Altimmune
2.67
Moderate Buy$15.00119.62% Upside
Penumbra, Inc. stock logo
PEN
Penumbra
2.78
Moderate Buy$304.4550.79% Upside
PTRO
Petrominerals
N/AN/AN/AN/A

Current Analyst Ratings

Latest PTRO, ODA, ALT, PEN, and IHR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/3/2024
Penumbra, Inc. stock logo
PEN
Penumbra
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$290.00
4/1/2024
Altimmune, Inc. stock logo
ALT
Altimmune
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$15.00 ➝ $12.00
3/28/2024
Altimmune, Inc. stock logo
ALT
Altimmune
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00
3/22/2024
Penumbra, Inc. stock logo
PEN
Penumbra
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$290.00 ➝ $280.00
2/23/2024
Penumbra, Inc. stock logo
PEN
Penumbra
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$310.00 ➝ $290.00
2/23/2024
Penumbra, Inc. stock logo
PEN
Penumbra
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$289.00
2/23/2024
Penumbra, Inc. stock logo
PEN
Penumbra
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$284.00
2/23/2024
Penumbra, Inc. stock logo
PEN
Penumbra
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$300.00 ➝ $290.00
2/23/2024
Penumbra, Inc. stock logo
PEN
Penumbra
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOverweight ➝ Neutral$284.00 ➝ $250.00
2/13/2024
Altimmune, Inc. stock logo
ALT
Altimmune
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00
1/24/2024
Altimmune, Inc. stock logo
ALT
Altimmune
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral$13.00
(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Altimmune, Inc. stock logo
ALT
Altimmune
$430K1,126.00N/AN/A$2.75 per share2.48
Penumbra, Inc. stock logo
PEN
Penumbra
$1.06B7.38$2.74 per share73.80$30.55 per share6.61
PTRO
Petrominerals
N/AN/AN/AN/AN/AN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Altimmune, Inc. stock logo
ALT
Altimmune
-$88.45M-$1.65N/AN/AN/A-20,780.75%-44.77%-40.72%5/9/2024 (Estimated)
Penumbra, Inc. stock logo
PEN
Penumbra
$90.95M$2.3187.4150.732.068.59%7.49%5.60%5/7/2024 (Confirmed)
PTRO
Petrominerals
N/AN/A0.00N/AN/AN/AN/AN/AN/A

Latest PTRO, ODA, ALT, PEN, and IHR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2024N/A
Penumbra, Inc. stock logo
PEN
Penumbra
$0.42N/A-$0.42N/AN/AN/A  
2/22/2024Q4 2023
Penumbra, Inc. stock logo
PEN
Penumbra
$0.71$0.76+$0.05$0.14$286.62 million$284.68 million      

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Altimmune, Inc. stock logo
ALT
Altimmune
N/AN/AN/AN/AN/A
Penumbra, Inc. stock logo
PEN
Penumbra
N/AN/AN/AN/AN/A
PTRO
Petrominerals
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Altimmune, Inc. stock logo
ALT
Altimmune
N/A
17.26
17.26
Penumbra, Inc. stock logo
PEN
Penumbra
0.02
6.06
3.49
PTRO
Petrominerals
N/AN/AN/A

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Altimmune, Inc. stock logo
ALT
Altimmune
78.05%
Penumbra, Inc. stock logo
PEN
Penumbra
88.88%
PTRO
Petrominerals
N/A

Insider Ownership

CompanyInsider Ownership
Altimmune, Inc. stock logo
ALT
Altimmune
4.10%
Penumbra, Inc. stock logo
PEN
Penumbra
5.30%
PTRO
Petrominerals
9.99%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Altimmune, Inc. stock logo
ALT
Altimmune
5970.89 million67.99 millionOptionable
Penumbra, Inc. stock logo
PEN
Penumbra
4,20038.70 million36.65 millionOptionable
PTRO
Petrominerals
11.33 millionN/ANot Optionable

PTRO, ODA, ALT, PEN, and IHR Headlines

No headlines for this company have been tracked by MarketBeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Altimmune logo

Altimmune

NASDAQ:ALT
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
Penumbra logo

Penumbra

NYSE:PEN
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX Select, BENCHMARK, BMX96, BMX81, DDC, SENDit, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization Device, aspiration tubing, and aspiration pump under the Penumbra RED, JET, ACE, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as Penumbra SMART COIL, a detachable coil to treat patients with a wide range of neurovascular lesions; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers an immersive 3D computer-based technology platform under the real immersive system brand; and neurosurgical tools, such as Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.

Petrominerals

OTCMKTS:PTRO
Petrominerals Corporation engages in the exploration, drilling, and production of oil and gas; and other oil industry-related businesses. It owns interests in oil producing properties in southern California. The company has a 53% working interest in the Castaic Hills Unit; a 100% working interest in a single oil well; and a 83.3% working interest in two oil wells in the Hasley Canyon field. Its properties are located in Santa Clarita, California. The company's net production of oil and gas was approximately 8 million barrels, as of December 31, 2003. It had approximately 23 gross oil and gas producing wells, as of the above date. Petrominerals Corporation was founded in 1966 and is based in Ventura, California.